83.9 F
San Fernando
Friday, Jan 27, 2023
-Advertisement-
Array

Kythera Drug Wins FDA Approval

A fat-dissolving drug from Kythera Biopharmaceuticals Inc. that reduces double chins was approved by the Food and Drug Administration Wednesday. The injectable drug, called Kybella, will be the first commercial product for the Westlake Village biotech. Previously, the drug was called ATX-101. According to Kythera, it is the only FDA-approved, non-surgical treatment for chin fat. “With Kybella, physicians can offer a clinically proven treatment that is customized to the patient and their treatment goals for an improved chin profile,” Chief Executive Keith Leonard said in a statement. Kythera has spent about 10 years and more than $307 million to achieve FDA approval. The company is also working on a male-pattern baldness medication. Shares closed down $2.05 or 4.3 percent to $45.59 on the Nasdaq.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-